

1 **Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge**
2 **model**
3
4

5 Adam T. Waickman^{1,2}, Krista Newell¹, Joseph Q. Lu^{1,2}, HengSheng Fang¹, Mitchell Waldran¹,
6 Chad Gebo¹, Jeffrey R. Currier³, Heather Friberg³, Richard G. Jarman³, Michelle D. Klick², Lisa
7 A. Ware², Timothy P. Endy¹, Stephen J. Thomas^{1,2}
8

9 ¹Department of Microbiology and Immunology, State University of New York Upstate Medical
10 University, Syracuse, NY 13210, USA.
11

12 ²Institute for Global Health and Translational Sciences, State University of New York Upstate
13 Medical University, Syracuse, NY 13210, USA.
14

15 ³Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland,
16 United States of America.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Keywords:** DENV, dengue human infection model, inflammation, infection

47 **Abstract** (150 words):

48
49 Dengue human infection models present an opportunity to explore a vaccine, antiviral, or
50 immuno-compound's potential for clinical benefit in a controlled setting. Herein, we report the
51 outcome of a phase 1, open-label assessment of a DENV-3 challenge model. In this study, 9
52 participants received a subcutaneous inoculation with 0.5ml of a 1.4×10^3 PFU/ml suspension of
53 the DENV-3 strain CH53489. All subjects developed RNAemia within 7 days of inoculation,
54 with peak titers ranging from 3.13×10^4 to 7.02×10^8 GE/ml. Symptoms and clinical lab
55 abnormalities consistent with mild dengue infection were observed in all subjects. DENV-3
56 specific seroconversion was observed by 14 days after inoculation, along with DENV-3 specific
57 memory T cell responses. RNAseq and serum cytokine analysis revealed the presence of an
58 antiviral transcriptional and cytokine response to infection that overlapped with the period of
59 viremia. The magnitude and frequency of clinical and immunologic endpoints correlated with an
60 individual's peak viral titer.

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82

83 INTRODUCTION

84
85 Dengue is an expanding global public health threat in predominantly tropical and subtropical
86 regions [1, 2]. Dengue is caused by infection with any of the four DENV types; each being
87 virologically related but genetically and antigenically distinct [3]. *Aedes* mosquito species are the
88 primary vectors of DENV transmission and changes in climate have expanded their habitat
89 allowing for local transmission in historically more temperate regions [4, 5].

90
91 It is estimated there are up to 400 million DENV infections every year, with more than 90
92 million resulting in clinically relevant disease [1, 2, 6]. Infection may result in an asymptomatic
93 or subclinical infection or classic dengue fever [3, 7]. Severe dengue occurs in a minority of
94 infections, approximately 2-4% of people experiencing a sequential infection with a different
95 DENV type more than 18 months following their first infection [8-10]. Severe dengue may
96 manifest as plasma leakage, hemorrhage, end organ dysfunction, and death [8, 9, 11]. Current
97 treatment is primarily based on symptom relief and judicious intravascular volume replacement
98 with fluids [12, 13].

99
100 Currently, there are no antivirals approved for the prevention or treatment of DENV infections.
101 There are also no immuno-compounds (i.e., monoclonal antibodies) approved for the prevention
102 or treatment of dengue. A single dengue vaccine (Sanofi Pasteur, Dengvaxia[®]) has been
103 approved for use in numerous countries, but uptake has been low due to the need to assess
104 dengue serostatus prior to vaccination, and an observed safety signal in children who were
105 seronegative at the time of vaccination [14-16]. Takeda Vaccines has recently received approval
106 for use of their vaccine (TAK-003) in Indonesia without the restriction of needing to confirm
107 serostatus prior to vaccination [17-19]. The company is pursuing additional regulatory approvals.
108

109 Developing countermeasures against dengue has been challenging for a number of reasons,
110 including; 1) the existence of four DENVs, each capable of causing disease and death, 2) an
111 incomplete understanding of what constitutes an immuno-protective versus immuno-pathologic
112 profile prior to infection; 3) the inability to precisely measure homotypic, non-cross reactive
113 DENV immune responses; and 4) the absence of an animal model of disease which accurately
114 recapitulates the human infection experience [20, 21].

115
116 For these reasons, a consortium of investigators has continued over a century of work devoted to
117 developing a safe dengue human infection model (DHIM) [22]. The intent of the DHIM is to
118 expose healthy volunteers to under-attenuated DENVs and create a mild and uncomplicated
119 dengue illness. The objective is to intensely study signs and symptoms of dengue, clinical lab
120 abnormalities, virologic, and innate and adaptive immune responses. Knowing the exact
121 infecting DENV type and time of exposure allows investigators to explore, in detail, the kinetics
122 of clinical, virologic, serologic, and immunologic responses to infection.

123
124 The DHIM is not intended to study moderate or severe dengue, but to drastically improve upon
125 the limitations of current small animal and non-human primate models of uncomplicated dengue
126 disease. A safe and consistently performing DHIM representing each of the four DENV types
127 would be a powerful tool supporting the development of dengue vaccines, treatments, and non-
128 vaccine prophylactics. A DHIM capable of assessing, early in development, the potential for

129 clinical benefit of a countermeasure could prevent thousands of volunteers having to be exposed
130 to ineffective countermeasure candidates.

131
132 In this manuscript we describe our clinical characterization of a DENV-3 DHIM viral strain. In
133 this study, we screened and enrolled 9 flavivirus naïve, healthy adults. Each volunteer was
134 subcutaneously inoculated with 0.5ml of a 1.4×10^3 PFU/ml suspension of the DENV-3 strain
135 CH53489 manufactured under Good Manufacturing Practices. The trial was conducted following
136 U.S. Food and Drug Administration acceptance of an Investigational New Drug application and
137 local Institutional Review Board approval. Following inoculation, volunteers were assessed daily
138 or every other day for 28 days. Follow-up visits also occurred at more remote timepoints out to
139 180 days. Blood samples were collected to assess safety and virologic, serologic, and
140 immunologic responses to infection.

141 142 **RESULTS**

143
144 **Virologic characteristics of CH53489 strain DENV-3 challenge.** Nine participants
145 (**Supplemental Table 1**) were enrolled in this study to receive a single subcutaneous inoculation
146 with 0.5ml of a 1.4×10^3 PFU/ml suspension of the DENV-3 strain CH53489 [23, 24].
147 Participants in this study were evaluated daily for the first 14 days after inoculation either in-
148 person or by phone, then every other day until 28 days post virus inoculation with additional
149 visits on days 90 and 180 post infection (**Supplemental Figure 1**). Participants were admitted to
150 SUNY Upstate Medical University Hospital for observation if they met pre-defined
151 hospitalization criteria. Six of nine study participants were admitted for observation during the
152 course of the study. As with previous DENV-1 challenge studies, all participants who became ill
153 were managed with oral fluids, acetaminophen, and an anti-nausea medication if required. No
154 intravenous access was required. In the event of hospitalization, study participants were shifted
155 to an alternative sample collection schedule where safety and research blood draws were
156 collected daily for the duration of the hospital stay and additional research draws collected three-
157 and seven-days post discharge. All nine enrolled participants completed the study per protocol
158 and were included in the subsequent virologic and immunologic analyses.

159
160 All study participants developed detectable RNAemia and viremia as assessed by qRT-PCR and
161 Vero cell-based plaque assay, respectively, while 8 of 9 study participants experienced
162 quantifiable NS1 antigenemia (**Figure 1A, Figure. 1B, Figure 1C**). The incubation period (time
163 from infection to detectable RNAemia) ranged from 3 to 6 days (mean 4.1 days post challenge)
164 (**Figure 1D**), with peak viral loads occurring 6 to 8 days post challenge (mean 6.7 days post
165 challenge) (**Figure 1E**). Peak viral load ranged from 3.13×10^4 to 7.02×10^8 genome equivalents
166 (GE)/mL, or 5.3×10^3 to 3.0×10^7 plaque forming units (PFU)/mL of serum, with detectable
167 viremia (day of first detection until first day below detection) lasting 4 to 11 days (mean of 7.3
168 days). DENV NS1 antigenemia was detected on average 3.1 days later than RNAemia or
169 viremia, with the day of detectible NS1 antigenemia ranging between 6 to 12 days post challenge
170 (mean 7.3 days), persisting for an average (mean) of 12.25 days across all NS1 antigen positive
171 study participants (**Fig. 1C**).

172
173 **Clinical characteristics of CH53489 strain DENV-3 challenge.** Within the first 14 days
174 following inoculation 9/9 study participants reported at least one solicited systemic AE. Rash

175 was observed in 7/9 subjects, which was evident for between 3 and 20 days per individual
176 (median of 9 days), with 4/9 reporting severe rash based on the percent of body surface area
177 involved (**Figure 2A**). Fatigue was described by 7/9 subjects, lasting for 3-12 days (median of 6
178 days) (**Figure 2B**). Headache was described by 8/9 subjects and was experienced for 1 to 11
179 days per subject (median of 3 days) (**Figure 2C**). Fever – defined as a temperature equal to or
180 greater than 100.4°C - was observed in 8/9 individuals, lasting for 1 to 5 days per subject
181 (median 2 days), with one subject experiencing severe ($\geq 102.1^{\circ}\text{C}$) fever (**Figure 2D**).

182
183 All study participants had at least 1 laboratory abnormality between days 1 and 28 post DENV-3
184 strain CH53489 challenge, the majority of which were mild or moderate. At least 1 severe
185 laboratory abnormality was reported by 5 of the 9 participants. Elevated liver enzyme levels
186 (ALT/AST) were observed in 5/9 study participants with 2 individuals classified as severe and
187 all returning to normal ranges within 30 days post challenge (**Figure 3A, Figure 3B**). No
188 hemoconcentration was observed in any subject during the course of the study (**Figure 3C**).
189 Lymphopenia was observed in 9/9 subjects (3 severe), while neutropenia was observed in 7/9
190 subjects (2 severe), and thrombocytopenia observed in 4/9 study participants (1 severe) (**Figure**
191 **3D, Figure 3E, Figure 3F**).

192
193 **Kinetics and specificity of DENV-3 elicited humoral immunity.** Having established the
194 virologic and clinical features of CH53489 human challenge we next assessed the induction of
195 DENV-3 specific adaptive immunity. Using a virion-capture ELISA assay we observed the
196 induction of a robust DENV-3 specific IgM response in all participants first detectible between
197 days 9 and 14 post infection and persisting above baseline in 8/9 subjects for at least 90 days
198 (**Figure 4A, Figure 4B**). A transient DENV-3 specific IgA response was also observed starting
199 between days 12 and 15 post challenge, dropping below the threshold of detection in 7/9 subjects
200 by day 90 post infection (**Figure 4A, Figure 4B**). DENV-3 specific IgG was detected in
201 circulation observed starting between days 14 and 28 post challenge, remaining above the
202 threshold of detection in 8/9 for at least 90 days post infection (**Figure 4A, Figure 4B**).

203
204 In addition to assessing the abundance of virion-specific antibodies, the abundance of NS1-
205 specific antibodies elicited by CH53489 infection were quantified using cell-based NS1
206 opsonization assay. We utilized a CEM.NK^R cell line that was engineered to stably express
207 DENV-3 NS1 and quantified the abundance of anti-NS1 opsonizing antibodies using flow
208 cytometry (**Supplemental Figure 3**). Robust induction of anti-NS1 IgM antibodies was observed
209 in all study participants first starting between days 8 and 28 post infection, with IgG isotype
210 responses appearing later and persisting through day 90 post infection (**Figure 4C, Figure 4D**).
211 Only modest and transient anti-NS1 IgA antibody titers were observed following CH53489
212 challenge (**Figure 4C, Figure 4D**).

213
214 Consistent with the robust humoral immune response elicited by CH53489 challenge, IFN- γ
215 ELISPOT analysis of PBMC collected from study participants on days 0, 28 and 90 post
216 infection demonstrated the presence of a significant adaptive cellular immune response to
217 infection. Stimulation with overlapping peptide pools spanning the E, NS1, NS3, and NS5
218 proteins demonstrated the induction of significant cellular immune responses against all antigens
219 included in the analysis, which NS3, NS5 and E proteins exhibiting higher responses on average
220 than NS1 (**Figure 4E, Supplemental Figure 4**). In their totality these results demonstrate that

221 CH53489 challenge results in the development of robust DENV-3 specific humoral and cellular
222 immunity that persists for at least 90 days post infection.

223
224 **Transcriptional profiling of CH53489-elicited immune activation.** In light of the robust
225 adaptive immune response elicited by CH53489 challenge we next endeavored to define the
226 early transcriptional profile of DENV-3 elicited inflammation. Accordingly, we performed
227 RNAseq analysis on whole blood samples collected on or around days 0, 6, 8, 10, 14 and 28 post
228 CH53489 challenge in all 9 study participants. These time points were selected to capture both
229 the peak of viral replication (days 6-8 post infection) as well as the days when the induction of
230 the adaptive immune response was predicted to occur (day 10-14). Due to the adaptive nature of
231 the study protocol sample collections were not synchronous across all study participants.
232 Samples were binned into the nearest common study day (0, 6, 8, 10, 14, or 28) for subsequent
233 analysis (**Supplemental Table 2**).

234
235 Robust transcriptional deviations away from the day 0 transcriptional baseline were observed on
236 days 6, 8, 10, and 14 post infection, with all participants returning to a baseline transcriptional
237 state by day 28 post infection (**Figure 5A**). A total of 205 (196 upregulated, 9 downregulated),
238 302 (247 upregulated, 55 downregulated), 245 (195 upregulated, 50 downregulated) and 295
239 (267 upregulated, 28 downregulated) differentially expressed genes were observed on days 6, 8,
240 10, and 14, respectively (**Figures 5B-E, Supplemental Tables 3-6**). No differentially expressed
241 gene were observed on day 28 relative to day 0. Significant overlap was observed between the
242 differentially expressed genes detected on days 6, 8, and 10, while day 14 was characterized by a
243 mostly independent set of differentially expressed gene products (DEGs) (**Figure 5F,**
244 **Supplemental Figure 5**).

245
246 Ingenuity Pathway Analysis (IPA) of the DEGs identified in this study revealed that days 6, 8,
247 and 10 were dominated by the expression of gene products associated with interferon signaling,
248 chemokine/cytokine production, and the induction of antiviral responses (**Table 1,**
249 **Supplemental Figure 6, Supplemental Tables 7-9**). Gene pathways consistent with nascent B
250 cell activation and antibody production were also observed on days 10 and 14 post DENV-3
251 infection, with the day 14 gene profile dominated by terms associated with mitotic cell division
252 and lymphocyte proliferation (**Table 1, Supplemental Figure 6, Supplemental Tables 9-10**).
253 Consistent with these transcriptional profiles, elevated levels of IL-1Ra, IL-8, IFN- β , IL-10, and
254 IFN- α 2a were observed in serum collected from subjects on days 6, 8 and 10 post challenge
255 (**Supplemental Figure 7**), while IFN- γ , IL-10, and IL-9 were additionally detected starting on
256 day 10 post infection (**Supplemental Figure 8**). No statistically significant differences in
257 VEGFA, TNF α , MIP-1a, GM-CSF, MCP1, IL-1 β , IL-12p70, G-CSF, IL-6, IL-4 or IL-5 levels
258 were observed (**Supplemental Figure 9**).

259
260 To provide additional insight into the kinetics and relative magnitude of DENV-3 elicited
261 inflammation captured in the study we utilize a previously described DENV transcriptional
262 inflammation index to score each visit for each subject. Using this metric, the transcriptional
263 signature of DENV-elicited inflammation peaked in all individuals between days 6 and 8 post
264 challenge, returning to near baseline levels by day 14 post challenge mirroring the kinetics of
265 viremia observed in this study (**Figure 4G**). Furthermore, the abundance of unique IGH clones
266 assembled from the unenriched RNAseq data – a surrogate indicator of activated B cell

267 frequency – exhibited a significant increase from baseline starting on day 10 post infection,
268 peaking in all individuals on day 14, and returning to baseline by day 28 (**Figure 5H**).

269
270 **DENV-3 elicited plasmablast profiling.** In light of the robust B cell activation profile observed
271 by RNAseq following CH53489 infection we endeavored to better define the clonal and
272 transcriptional diversity of activated B cells (plasmablasts) elicited by DENV-3 infection in the
273 study. To this end, CD38+CD27+ plasmablast-phenotype CD19+ B cells were sorted from the
274 PBMC of four subjects with the most robust B cell activation profile by as defined by RNAseq
275 analysis (**Figure 6A, supplemental Figure 10**). After sorting, these purified plasmablasts were
276 subjected to scRNAseq analysis using the 10xGenomics platform. This resulted in the capture of
277 15,717 DENV-elicited plasmablasts with full-length/paired immunoglobulin sequences.

278
279 Consistent with our previously published report analyzing the plasmablast profile elicited by
280 natural primary DENV infection [25], three of the four subjects included in this analysis
281 exhibited a significant IgA1/IgM isotype bias with numerous large/expanded clonal families,
282 while one subject exhibited a more IgG1/IgM isotype bias with significantly less clonal
283 expansion (**Figure 6B, Figure 6C, Figure 6D**). Many clonal families were observed with
284 members with IgM, IgA, and IgG Fc regions (**Figure 6C, Figure 6D**). Relatively low levels of
285 somatic hypermutation (SHM) were observed in IgM and IgG isotype antibodies captured in this
286 analysis, with IgA isotype antibodies on average exhibited significantly higher SHM burdens
287 than their IgM and IgG counterparts.

288
289 **Virologic and immunologic correlates of clinical dengue.** We next endeavored to clarify the
290 correlative relationships between the individual virologic, clinical, and immunologic parameters
291 captured in this analysis. We selected three virologic parameters (peak RNAemia, viremia, and
292 NS1 antigenemia), four clinical parameters (days with rash, fatigue, headache, or fever), five
293 clinical labs (AUC of ALT, AST, WBC, neutrophil and platelet counts outside of normal range),
294 seven immunologic parameters (DENV-specific IgM/IgA/IgG AUC, NS1-specific IgM/IgA/IgG
295 AUC, and day 90 ELISPOT counts), five serum cytokine features (IL-1Ra, IP-10, IFN-A2a,
296 IFNg, and IL-10 AUC), and two transcriptional features (inflammation score and number of peak
297 annotated IGH clones) for inclusion in this analysis (**Figure 7A**).

298
299 All virologic parameters exhibited a high degree of correlation with multiple clinical parameters
300 such as number of days with fever and ALT/AST levels (**Figure 7A, Figure 7B, Figure 7C**). In
301 addition, peak viral loads correlated with DENV-specific IgM and IgG titers, and anti-NS1 IgG
302 titers (**Figure 7A, Figure 7D, Figure 7E**). These results support a model wherein the incidence
303 and severity of mild DENV-elicited clinical pathology – as well as the magnitude of DENV-
304 elicited adaptive immunity – is directly proportional to viral burden in previously flavivirus
305 naïve individuals.

306
307

308 **DISCUSSION**

309
310 In this study we precisely define the virologic, immunologic, and clinical features associated
311 with a primary DENV-3 infection in flavivirus-naïve adults. This includes the kinetics and
312 composition of the innate, humoral, cellular, and transcriptional responses elicited by

313 experimental DENV-3 infection, as well as the virologic and clinical features of DENV-3
314 infection in 9 individuals inoculated with the under-attenuated DENV-3 strain CH53489. A
315 notable feature of the results presented in our current study is the strong correlation observed
316 between peak viral load and the frequency and magnitude of the clinical and immunological
317 features elicited by DENV-3 infection. While the relationship between peak viral load, symptom
318 severity, and subsequent anti-DENV immune profiles has been well established in individuals
319 experiencing clinically apparent dengue [7], to our knowledge this is the first time this
320 relationship has been extended to include individuals with mild or asymptomatic primary DENV
321 infections. Importantly, these results support the utility of dengue human challenge models in
322 evaluating the potential clinical benefit of candidate anti-dengue countermeasures where
323 reduction in disease burden through the reduction in viral replication is an objective.

324
325 In addition to the spectrum of virologic and clinical features of primary DENV-3 infection
326 captured in this analysis, several notable immunologic responses to CH53489 infection were
327 observed. This includes a robust IgA1-biased plasmablast response after the resolution of acute
328 viremia and infection-elicited inflammation. The presence of an IgA-dominated plasmablast
329 response following primary DENV infection has now been described by multiple groups using
330 several different analytic approaches [25-28]. However, the origin of this IgA biased response
331 remains unclear. The extensive hypermutation burden present in these IgA class-switched
332 plasmablasts might suggest that these cells arose from a pool of pre-existing IgA1 class-switched
333 memory B cells that cross-react with DENV antigens. However, data presented in this study
334 suggest this might not be the case, as B cell clones that have class-switched to IgM, IgG, and IgA
335 are observed. These results are more consistent with a model wherein the IgA1 isotype
336 plasmablasts arose from the same population of naïve B cells as IgM and IgG1 isotype cells. In
337 addition, the transient nature of this DENV-elicited IgA response suggests that these cells are
338 unable to take up residency in the bone marrow as long-lived plasma cells. While the biological
339 significance of this observation is unclear, the short-lived nature of serum-derive DENV-specific
340 IgA produced following both natural and experimental DENV infection has interesting
341 implications from an epidemiological and serosurveillance perspective.

342
343 There are some limitations of this study to consider. Firstly, the relatively small number of
344 subjects included in this analysis limits the generalizability of the observations. Secondly, the
345 virus used in this study is delivered by intradermal injection rather than by an infected mosquito.
346 The presence of mosquito saliva and/or salivary proteins (MSPs) has been shown to impact the
347 kinetics and magnitude of DENV viremia in several experimental models of DENV infection
348 [29], and it is currently unclear how the absence of this signal impacts the virologic and clinical
349 progression of DENV infection in humans.

350
351 In conclusion, we have demonstrated the ability to safely infect flavivirus naïve volunteers with
352 an under-attenuated DENV-3 strain CH53489. This infection results in a dengue-like illness with
353 symptoms, clinical lab abnormalities, and immune responses consistent with an uncomplicated
354 natural DENV infection. We demonstrated the magnitude and frequency of symptoms and
355 immunologic features correlated with peak viremia titers. The acute/innate immune response to
356 CH53489 is evident as early as 6 days post infection and persists through at least 10 days post
357 infection, with the induction of an adaptive anti-DENV immune response evident 14 days post
358 infection. These results provide hitherto unachievable insight into the kinetics and composition

359 of DENV-3 elicited immune responses in flavivirus naïve individuals and provide an array of
360 DENV-elicited biomarkers that can inform the development and characterization of anti-DENV
361 countermeasures.

362
363
364

MATERIALS AND METHODS

365

366 **Dengue human infection model.** The Dengue Human Infection Model and associated analysis
367 was approved by the State University of New York Upstate Medical University (SUNY-UMU)
368 and the Department of Defense’s Human Research Protection Office. This phase 1, open-label
369 study (ClinicalTrials.gov identifier: NCT04298138) was conducted between August 2020 and
370 July 2021 at the State University of New York, Upstate Medical University (SUNY-UMU) in
371 Syracuse, New York. Participants received a single subcutaneous inoculation of 0.7×10^3 PFU
372 (0.5ml of a 0.7×10^3 PFU solution) of the CH53489 DENV-3 infection strain virus manufactured
373 at the WRAIR Pilot Bioproduction Facility, Silver Spring, MD (US FDA Investigational New
374 Drug 19321). All participants were pre-screened to ensure an absence of preexisting flavivirus
375 using the Euroimmun dengue, West Nile, and Zika IgG ELISA kits (Lübeck, Germany). Subjects
376 were monitored in an outpatient setting unless the hospitalization criteria were met.

377 Criteria for subject hospitalization included fever of > 101 at 2 time points at least 4 hours apart,
378 headache \geq grade 2, eye pain \geq grade 2, bone pain $>$ grade 2, joint pain $>$ grade 2, abdominal
379 pain $>$ grade 2, muscle pain $>$ grade 2, nausea and/or vomiting $>$ grade 2, liver function tests
380 (ALT, AST) $>$ grade 2, leukopenia $>$ grade 2, thrombocytopenia \geq grade 2, fatigue \geq grade 2, or
381 the presence any symptoms determined by the PI to warrant hospital admission. Study
382 participants were discharged when the following criteria were met: no fever ($< 100.4^\circ\text{F}$),
383 laboratory parameters resolving and were \leq grade 2 (at clinician discretion), and clinical
384 symptoms were resolving and were \leq grade 2 (at clinician discretion). Quantitative DENV-3
385 specific reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using
386 previously published techniques [30]. Serum NS1 antigen levels were quantified using a
387 Euroimmun dengue NS1 ELISA kit (Lübeck, Germany).

388

389 **DENV-3 virion-capture ELISA.** DENV-3 reactive serum IgM/IgA/IgG levels were assessed
390 using a flavivirus capture ELISA protocol. In short, 96 well NUNC MaxiSorb flat-bottom plates
391 were coated with $2 \mu\text{g/ml}$ flavivirus group-reactive mouse monoclonal antibody 4G2 (Envigo
392 Bioproducts, Inc.) diluted in borate saline buffer. Plates were washed and blocked with 0.25%
393 BSA +1% Normal Goat Serum in PBS after overnight incubation. DENV-3 (strain CH53489)
394 was captured for 2 hours, followed by extensive washing. Serum samples were serially diluted
395 four-fold, plated and incubated for 1 hour at room temperature on the captured virus. DENV-
396 specific IgM/IgG/IgA levels were quantified using anti-human IgM HRP (Seracare, 5220-0328),
397 anti-human IgG HRP (Southern BioTech, 2044-0), and anti-human IgA HRP (Biolegend,
398 411,002). Secondary antibody binding was quantified using the TMB Microwell Peroxidase
399 Substrate System (KPL, cat. #50-76-00) and Synergy HT plate reader. DENV-3 (strain
400 CH53489) was propagated in Vero cells and purified by ultracentrifugation through a 30%
401 sucrose solution. End-point titers were determined as the reciprocal of the final dilution at which
402 the optical density (OD) was greater than $2\times$ of a pool of control flavivirus naïve serum at the
403 same dilution. Day of seroconversion was defined as the day at which a participant’s end-point
404 titer exceeded that of their respective day 0 sample

405
406 **Anti-NS1 opsonization assay.** DENV-3 NS1 expressing CEM.NK^R cells (**fig. S3**) were stained
407 with a 1:50 dilution of heat-inactivated serum diluted in PBS at room temperature for 30 min.
408 Cells were extensively washed, then stained with goat anti-human IgA AF647 (2050-31,
409 Southern Biotech), goat anti-human IgG AF467 (2040-31, Southern Biotech), or goat anti-human
410 IgM AF647(2020-31, Southern Biotech). Flow cytometry analysis was performed on a BD
411 LSRII instrument, and data analyzed using FlowJo v10.2 software (Treestar). Reported MFI
412 values are background subtracted, with background defined as the signal observed staining
413 DENV-3 NS1 expressing CEM.NK^R cells in the absence of serum. Day of seroconversion was
414 defined as the day at which a participant's background-subtracted NS1 specific MFI increased by
415 at least 2× over their respective day 0 value.

416
417 **Serum cytokine analysis.** The abundance of cytokines/chemokines in patient serum was
418 assessed using the MSD human U-PLEX Viral Combo 1 kit and the MESO QuickPlex SQ 120
419 instrument (MESO Scale Diagnostics, Rockville, MD) according to the manufacture's
420 recommendation.

421
422 **IFN-γ ELISPOT.** Cryopreserved PBMC were thawed, washed twice, and placed in RPMI 1640
423 medium (Corning, Tewksbury, MA, USA) supplemented with 10% heat-inactivated fetal calf
424 serum (Corning, 35-010-CV), L-glutamine (Lonza, Basel, Switzerland), and
425 Penicillin/Streptomycin (Gibco, Waltham, MA, USA). Cellular viability was assessed by trypan
426 blue exclusion and cells were resuspended at a concentration of 5×10^6 /mL and rested overnight
427 at 37 °C. After resting, viable PBMC were washed, counted, and resuspended at a concentration
428 of 1×10^6 /mL in complete cell culture media. Next, 100 μL of this cell suspension was mixed
429 with 100 μL of the individual peptide pools listed in **Supplemental Table 11** and diluted to a
430 final concentration 1 μg/mL/peptide (DMSO concentration 0.5%) in complete cell culture media.
431 This cell and peptide mixture was loaded onto a 96-well PVDF plate coated with anti-IFN-γ
432 (3420-2HW-Plus, Mabtech, Nacka, Sweden) and cultured overnight. Controls for each
433 participant included 0.5% DMSO alone (negative) and anti-CD3 (positive). After overnight
434 incubation, the ELISPOT plates were washed and stained with anti-IFN-γ-biotin followed by
435 streptavidin-conjugated HRP (3420-2HW-Plus, Mabtech). Plates were developed using TMB
436 substrate and read using a CTL-ImmunoSpot[®] S6 Analyzer (Cellular Technology Limited,
437 Shaker Heights, OH, USA). All peptide pools were tested in duplicate, and the adjusted mean
438 was reported as the mean of the duplicate experimental wells after subtracting the mean value of
439 the negative (DMSO only) control wells. Individuals were considered reactive to a peptide pool
440 when the background-subtracted response was >50 spot forming cells (SFC)/10⁶ PBMC. All data
441 were normalized based on the number of cells plated per well and are presented herein as
442 SFC/10⁶ PBMC.

443
444 **RNA sequencing library preparation and sequencing.** Whole blood was collected from all
445 study participants using PAXgene RNA collection tubes (BD) and frozen at -20° C until
446 analyzed. RNA was recovered from the collection tubes using the Qiagen PAXgene Blood RNA
447 isolation Kit and sequencing libraries created using Illumina Stranded Total RNA Prep with
448 Ribo-Zero Plus and IDT-Ilmn RNA UD Indexes SetA. Final library QC and quantification was
449 performed using a Bioanalyzer (Agilent) and DNA 1000 reagents. Libraries were pooled at an

450 equimolar ratio and sequenced on a 300 cycle Novaseq 6000 instrument using v1.5 S4 reagent
451 set.

452
453 **RNA sequencing gene expression analysis.** Raw reads from demultiplexed FASTQ files were
454 mapped to the human reference transcriptome (Ensembl, Homo sapiens, GRCh38) using Kallisto
455 [31] version 0.46.2. Transcript-level counts and abundance data were imported and summarized
456 in R (version 4.0.2) using the TxImport package [32] and TMM normalized using the package
457 EdgeR [33, 34]. Differential gene expression analysis performed using linear modeling and
458 Bayesian statistics in the R package Limma [35]. Genes with a \log_2 fold change of >2 and a
459 Benjamini-Hochberg adjusted p-value < 0.01 were considered significant. Gene module scores
460 were calculated by summing the TMM normalized abundance (TPM) of the genes highlighted as
461 belonging to either Module 1 or Module 2 for all samples.

462
463 **BCR clonotype identification and annotation from bulk RNAseq.** Raw FASTQ files were
464 filtered to contain only pair-end reads and to remove any Illumina adaptor contamination and
465 low-quality reads using Trimmomatic (v0.39) [36]. Pair-end reads were subsequently analyzed
466 using MiXCR (v3.0.3) using the RNA-seq/non-targeted genomic analysis pipeline [37, 38].
467

468 **Flow cytometry and cell sorting.** Cryopreserved PBMC were thawed and placed in RPMI 1640
469 medium (Corning, Tewksbury, MA, USA) supplemented with 10% heat-inactivated fetal calf
470 serum (Corning, 35-010-CV), L-glutamine (Lonza, Basel, Switzerland), and
471 Penicillin/Streptomycin (Gibco, Waltham, MA, USA). Cellular viability was assessed by trypan
472 blue exclusion. Surface staining for flow cytometry analysis and cell sorting was performed in
473 PBS supplemented with 2% FBS at room temperature. Aqua Live/Dead (ThermoFisher, L34957)
474 was used to exclude dead cells in all experiments. Antibodies and dilutions used for flow
475 cytometry analysis are listed in **Supplemental Table 12**. Cell sorting was performed on a BD
476 FACSAria III instrument, with cells sorted directly into 50 ul of complete cell culture media
477 supplemented with 20% FCS. Data analyzed using FlowJo v10.2 software (Treestar).
478

479 **Single-cell RNA sequencing library generation.** Flow-sorted viable CD3-CD56-CD14-
480 CD19+CD27+CD38+ plasmablast phenotype B cells were prepared for single-cell RNA
481 sequencing using the Chromium NextGEM Single-Cell 5' Reagent version 2 kit and Chromium
482 Single-Cell Controller (10x Genomics, CA) [39]. Approximately 2000–8000 cells per reaction
483 suspended at a density of 50–500 cells/ μL in PBS plus 0.5% FBS were loaded for gel bead-in-
484 emulsion (GEM) generation and barcoding. Reverse transcription, RT-cleanup, and cDNA
485 amplification were performed to isolate and amplify cDNA for enriched V(D)J library
486 construction according to the manufacturer's protocol. Libraries were constructed using the
487 Chromium Single-Cell 5' reagent kit, V(D)J Human B Cell Enrichment Kit, and Dual Index Kit
488 (10x Genomics, CA) according to the manufacturer's protocol.
489

490 **Single-cell RNA sequencing library Sequencing.** scRNAseq BCR V(D)J enriched libraries
491 were sequenced on an Illumina NextSeq 2000 instrument using the 300 cycle P1 reagent kit.
492 Libraries were balanced to allow for $\sim 10,000$ reads/cell for BCR V(D)J enriched libraries.
493 Sequencing parameters were set for 150 cycles for Read1, 10 cycles for Index1, 10 cycles for
494 Index2, and 150 cycles for Read2. Prior to sequencing, library quality and concentration were

495 assessed using an Agilent 4200 TapeStation with High Sensitivity D5000 ScreenTape Assay
496 according to the manufacturer's recommendations.

497
498 **Immunoglobulin sequence analysis.** Sorted B cell immunoglobulin clonotype identification,
499 alignment, and annotation was performed using the 10x Genomics Cell Ranger pipeline [39]
500 Sample demultiplexing and clonotype alignment was performed using the Cell Ranger software
501 package (10x Genomics, CA, v5.0.0) and bcl2fastq2 (Illumina, CA, v2.20) according to the
502 manufacturer's recommendations, using the default settings and mkfastq/vdj commands,
503 respectively. Immunoglobulin clonotype alignment was performed against a filtered human
504 V(D)J reference library. Paired immunoglobulin hypermutation burden was assessed using the
505 software package BRILIA [40], and clonal lineages defined and visualized using the enclone
506 software suite from 10xGenomics.

507
508 **Statistical analysis.** All statistical analyses other than RNAseq gene expression analysis was
509 performed using GraphPad Prism 9 Software (GraphPad Software, La Jolla, CA). A P-
510 value ≤ 0.05 was considered significant.

511
512

513 **ACKNOWLEDGEMENTS**

514

515 We gratefully acknowledge excellent technical assistance provided by Karen Gentile of the
516 Upstate Medical University Molecular Analysis Core (MAC), Lisa Phelps of the SUNY Upstate
517 Medical University Flow Cytometry Core, Holly Chanatry, and the members of the Institute for
518 Global Health and Translational Science (IGHTS) of SUNY Upstate Medical University. We
519 also acknowledge Calli Rooney from the US Army. We also wish to thank all the study
520 participants for making this study possible. The following reagents were obtained through BEI
521 Resources, NIAID, NIH: Peptide Array, DENV-3 Sleman/1978, E protein (NR-511), DENV-3
522 Philippines/H87/1956, E protein (NR-9228), DENV-1 Philippines/H87/1956, NS1 protein (NR-
523 2753), DENV-3 Philippines/H87/1956, NS3 protein (NR-2754), DENV-3 Philippines/H87/1956,
524 NS5 protein (NR-4204). The opinions or assertions contained herein are the private views of the
525 authors and are not to be construed as reflecting the official views of the US Army or the US
526 Department of Defense. Material has been reviewed by the Walter Reed Army Institute of
527 Research. There is no objection to its presentation and/or publication. The investigators have
528 adhered to the policies for protection of human participants as prescribed in AR 70-25.

529

530 **Funding:** Funding for this research was provided by the Department of Defense, Medical
531 Research and Material Command, the Military Infectious Disease Research Program, and the
532 State of New York.

533

534 **Author contributions.** Conceptualization: L.W., M.D.K, R.G.J., T.P.E., and S.J.T. Formal
535 analysis: L.W., A.T.W. Funding acquisition: H.F, R.G.J., T.P.E., and S.J.T. Investigation:
536 A.T.W., J.Q.L., K.N., H.S.F., M.W., C.G., M.D.K., L.W., T.P.E., S.J.T. Resources: H.F., R.G.J.,
537 J.R.C. Visualization: K.N., A.T.W. Writing – original draft: A.T.W., S.J.T. Writing – review &
538 editing: all authors

539

540 **Competing interests:** All authors: No reported conflicts of interest.

- 541
542 **Data availability.** The authors declare that all data supporting the findings of this study are
543 available within this article and its Supplementary Information files, or from the corresponding
544 author upon reasonable request. RNAseq gene expression data have been deposited in the NCBI
545 Gene Expression Omnibus (GEO GSE216328).
546
547
- 548 1. Bhatt, S., et al., *The global distribution and burden of dengue*. Nature, 2013. **496**(7446):
549 p. 504-7.
 - 550 2. Shepard, D.S., et al., *Economic impact of dengue illness in the Americas*. Am J Trop Med
551 Hyg, 2011. **84**(2): p. 200-7.
 - 552 3. Guzman, M.G., et al., *Dengue infection*. Nat Rev Dis Primers, 2016. **2**: p. 16055.
 - 553 4. Gubler, D.J., *Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top
554 down or bottom up. Charles Franklin Craig Lecture*. Am J Trop Med Hyg, 1989. **40**(6):
555 p. 571-8.
 - 556 5. Iwamura, T., A. Guzman-Holst, and K.A. Murray, *Accelerating invasion potential of
557 disease vector Aedes aegypti under climate change*. Nat Commun, 2020. **11**(1): p. 2130.
 - 558 6. World mosquito program. *Facts sheet Dengue*. [cited 2021 27 April]; Available from:
559 [https://www.worldmosquitoprogram.org/sites/default/files/2020-
560 11/WMP%20dengue_0.pdf](https://www.worldmosquitoprogram.org/sites/default/files/2020-11/WMP%20dengue_0.pdf).
 - 561 7. Vaughn, D.W., et al., *Dengue viremia titer, antibody response pattern, and virus serotype
562 correlate with disease severity*. J Infect Dis, 2000. **181**(1): p. 2-9.
 - 563 8. Anderson, K.B., et al., *A shorter time interval between first and second dengue infections
564 is associated with protection from clinical illness in a school-based cohort in Thailand*. J
565 Infect Dis, 2014. **209**(3): p. 360-8.
 - 566 9. Montoya, M., et al., *Symptomatic versus inapparent outcome in repeat dengue virus
567 infections is influenced by the time interval between infections and study year*. PLoS Negl
568 Trop Dis, 2013. **7**(8): p. e2357.
 - 569 10. Guzman, M.G., M. Alvarez, and S.B. Halstead, *Secondary infection as a risk factor for
570 dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of
571 antibody-dependent enhancement of infection*. Arch Virol, 2013. **158**(7): p. 1445-59.
 - 572 11. Srikiatkachorn, A., et al., *Natural history of plasma leakage in dengue hemorrhagic
573 fever: a serial ultrasonographic study*. Pediatr Infect Dis J, 2007. **26**(4): p. 283-90;
574 discussion 291-2.
 - 575 12. Rajapakse, S., et al., *Prophylactic and therapeutic interventions for bleeding in dengue: a
576 systematic review*. Trans R Soc Trop Med Hyg, 2017. **111**(10): p. 433-439.
 - 577 13. Wong, J.G., et al., *Identifying Adult Dengue Patients at Low Risk for Clinically
578 Significant Bleeding*. PLoS One, 2016. **11**(2): p. e0148579.
 - 579 14. Capeding, M.R., et al., *Clinical efficacy and safety of a novel tetravalent dengue vaccine
580 in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled
581 trial*. Lancet, 2014. **384**(9951): p. 1358-65.
 - 582 15. Villar, L., et al., *Efficacy of a tetravalent dengue vaccine in children in Latin America*. N
583 Engl J Med, 2015. **372**(2): p. 113-23.
 - 584 16. World Health, O., *Dengue vaccine: WHO position paper, July 2016 - recommendations.
585 Vaccine*, 2017. **35**(9): p. 1200-1201.

- 586 17. Biswal, S., et al., *Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and*
587 *Adolescents*. N Engl J Med, 2019. **381**(21): p. 2009-2019.
- 588 18. Biswal, S., et al., *Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16*
589 *years: a randomised, placebo-controlled, phase 3 trial*. Lancet, 2020. **395**(10234): p.
590 1423-1433.
- 591 19. *Takeda's QDENG A (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in*
592 *Indonesia for Use Regardless of Prior Dengue Exposure*. August 22, 2022:[Available
593 from: [https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-](https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure/)
594 [tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-](https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure/)
595 [dengue-exposure/](https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure/)].
- 596 20. Thomas, S.J. and T.P. Endy, *Current issues in dengue vaccination*. Curr Opin Infect Dis,
597 2013. **26**(5): p. 429-34.
- 598 21. Low, J.G., E.E. Ooi, and S.G. Vasudevan, *Current Status of Dengue Therapeutics*
599 *Research and Development*. J Infect Dis, 2017. **215**(suppl_2): p. S96-S102.
- 600 22. Endy, T.P., et al., *A Phase I, Open-Label Assessment of a Dengue Virus-1 Live Virus*
601 *Human Challenge Strain*. J Infect Dis, 2021. **223**(2): p. 258-267.
- 602 23. Mammen, M.P., et al., *Evaluation of dengue virus strains for human challenge studies*.
603 *Vaccine*, 2014. **32**(13): p. 1488-94.
- 604 24. Sun, W., et al., *Experimental dengue virus challenge of human subjects previously*
605 *vaccinated with live attenuated tetravalent dengue vaccines*. J Infect Dis, 2013. **207**(5): p.
606 700-8.
- 607 25. Waickman, A.T., et al., *Transcriptional and clonal characterization of B cell plasmablast*
608 *diversity following primary and secondary natural DENV infection*. EBioMedicine, 2020.
609 **54**: p. 102733.
- 610 26. Waickman, A.T., et al., *Temporally integrated single cell RNA sequencing analysis of*
611 *PBMC from experimental and natural primary human DENV-1 infections*. PLoS Pathog,
612 2021. **17**(1): p. e1009240.
- 613 27. Rouers, A., et al., *CD27(hi)CD38(hi) plasmablasts are activated B cells of mixed origin*
614 *with distinct function*. iScience, 2021. **24**(5): p. 102482.
- 615 28. Robinson, M.L., et al., *Magnitude and kinetics of the human immune cell response*
616 *associated with severe dengue progression by single-cell proteomics*. bioRxiv, 2022: p.
617 2022.09.21.508901.
- 618 29. McCracken, M.K., et al., *Route of inoculation and mosquito vector exposure modulate*
619 *dengue virus replication kinetics and immune responses in rhesus macaques*. PLoS Negl
620 Trop Dis, 2020. **14**(4): p. e0008191.
- 621 30. Houn, H.S., et al., *Development of a fluorogenic RT-PCR system for quantitative*
622 *identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3'*
623 *noncoding sequences*. J Virol Methods, 2001. **95**(1-2): p. 19-32.
- 624 31. Bray, N.L., et al., *Erratum: Near-optimal probabilistic RNA-seq quantification*. Nat
625 Biotechnol, 2016. **34**(8): p. 888.
- 626 32. Sonesson, C., M.I. Love, and M.D. Robinson, *Differential analyses for RNA-seq:*
627 *transcript-level estimates improve gene-level inferences*. F1000Res, 2015. **4**: p. 1521.
- 628 33. Robinson, M.D., D.J. McCarthy, and G.K. Smyth, *edgeR: a Bioconductor package for*
629 *differential expression analysis of digital gene expression data*. Bioinformatics, 2010.
630 **26**(1): p. 139-40.

- 631 34. McCarthy, D.J., Y. Chen, and G.K. Smyth, *Differential expression analysis of multifactor*
632 *RNA-Seq experiments with respect to biological variation*. Nucleic Acids Res, 2012.
633 **40**(10): p. 4288-97.
- 634 35. Ritchie, M.E., et al., *limma powers differential expression analyses for RNA-sequencing*
635 *and microarray studies*. Nucleic Acids Res, 2015. **43**(7): p. e47.
- 636 36. Bolger, A.M., M. Lohse, and B. Usadel, *Trimmomatic: a flexible trimmer for Illumina*
637 *sequence data*. Bioinformatics, 2014. **30**(15): p. 2114-20.
- 638 37. Bolotin, D.A., et al., *MiXCR: software for comprehensive adaptive immunity profiling*.
639 Nat Methods, 2015. **12**(5): p. 380-1.
- 640 38. Bolotin, D.A., et al., *Antigen receptor repertoire profiling from RNA-seq data*. Nat
641 Biotechnol, 2017. **35**(10): p. 908-911.
- 642 39. Zheng, G.X., et al., *Massively parallel digital transcriptional profiling of single cells*. Nat
643 Commun, 2017. **8**: p. 14049.
- 644 40. Lee, D.W., et al., *BRILIA: Integrated Tool for High-Throughput Annotation and Lineage*
645 *Tree Assembly of B-Cell Repertoires*. Front Immunol, 2016. **7**: p. 681.
- 646
647
648
649

650 **FIGURE LEGENDS**

651
652 **Figure 1. Viral kinetics of CH53489 challenge.** A) DENV-3 RNA content in serum as assessed
653 by qRT-PCR, B) Infectious DENV content in serum as assessed Vero cell plaque assay., C) NS1
654 protein content in serum as assessed by ELISA, D) Comparison of RNAemia, viremia, and NS1
655 antigenemia onset in all study participants, E) Comparison of peak RNAemia, viremia, and NS1
656 antigenemia in all study participants. ns not significant, ** $p < 0.01$, **** $p < 0.0001$, paired 1
657 way ANOVA with correction for multiple comparisons

658
659

660 **Figure 2. Timing and severity of clinically significant adverse events in response to**
661 **CH53489 challenge.** A) Rash, B) Fatigue, C) Headache, D) Fever

662
663

664 **Figure 3. Timing and magnitude of clinical lab abnormalities following CH53489 challenge.**
665 A) ALT, B) AST, C) HCT, D) WBC, E) Neutrophil count, F) Platelet count. All results shown
666 relative to screening visit value

667
668

669 **Figure 4. Kinetics and specificity of DENV-3 specific immunity elicited by CH53489**
670 **challenge.** A) Antibody endpoint titers using virion-capture ELISA. B) Day of virion-specific
671 IgM, IgA, and IgG seroconversion. C) Opsonizing anti-NS1 antibody staining using DENV-2
672 NS1 expressing CEM.NK^R cells D) Day of DENV-2 NS1-specific IgM, IgA, and IgG
673 seroconversion. E) Antigen specific breakdown of days 0, 28, and 90 DENV-3 specific cellular
674 immunity. Dashed line indicates 50 SFC/10⁶ PBMC.

675

676 **Figure 5. Kinetics and composition of DENV-3 elicited inflammation.** A) PCA plot of
677 RNAseq analysis of whole blood obtained on days 0, 6, 8, 10, 14, and 28 post CH53489
678 infection. Points colored by sample collection day. B) Volcano plot showing differential gene
679 expression day 0 vs day 6, C) day 0 vs day 8, D) day 0 vs day 10, and E) day 0 vs day 14 post
680 infection with select statistically and biologically significant genes highlighted. Genes with a
681 \log_2 fold change of >2 and an adjusted p-value < 0.01 were considered significant. F) Overlap of
682 Differentially Expressed Genes (DEG) observed on days 6, 8, 10 and 14 post CH53489
683 infection. G) Kinetics of previously defined inflammatory gene module expression across all 9
684 study participants and 6 time points. H) Identification and quantification of unique IGH clones
685 across all 9 study participants and 6 time points from the unenriched RNAseq data using
686 MiXCR.

687
688 **Figure 6. Isolation and clonal characterization of DENV-3 elicited plasmablasts.** A)
689 Identification and post-sort purity of DENV-3 elicited plasmablasts B) Isotype distribution of
690 DENV-3 elicited plasmablasts C) Clonal diversity and isotype distribution of all DENV-3
691 elicited plasmablasts D) Clonal diversity and isotype distribution of expanded ($n > 3$) DENV-3
692 elicited plasmablasts E) Somatic hypermutation burden of DENV-3 elicited plasmablasts
693 separated by isotype. **** $p < 0.0001$ one-way ANOVA with correction for multiple
694 comparisons.

695
696 **Figure 7. Correlation analysis of selection virologic, clinical, and immunologic features post**
697 **CH53489 challenge.** A) Correlation matrix. Spearman correlation. Only interactions with a $p <$
698 0.05 shown. B) Peak viremia vs total days with fever for each subject. C) Peak NS1 antigen
699 levels vs total days with fever for each subject D) Peak viremia vs virion-specific IgG AUC E)
700 Peak NS1 antigen levels vs NS1-specific IgG AUC

701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720

**Table 1. IPA analysis of differentially expressed genes defined by RNAseq on days 6, 8, 10,
and 14 post CH58349 infection**

Comparison	Ingenuity Canonical Pathways	$-\log(p\text{-value})$	Ratio	z-score
------------	------------------------------	-------------------------	-------	---------

Day 0 vs Day 6	Role of Hypercytokinemia/hyperchemokemia in the Pathogenesis of Influenza	1.98E+01	1.98E-01	3.638
Day 0 vs Day 6	Interferon Signaling	1.71E+01	3.33E-01	2.887
Day 0 vs Day 6	Activation of IRF by Cytosolic Pattern Recognition Receptors	9.22E+00	1.38E-01	1.667
Day 0 vs Day 6	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	7.97E+00	7.05E-02	2
Day 0 vs Day 6	Coronavirus Pathogenesis Pathway	6.80E+00	5.42E-02	-2.111
Day 0 vs Day 6	Role of PKR in Interferon Induction and Antiviral Response	5.35E+00	5.88E-02	2.646
Day 0 vs Day 6	Granulocyte Adhesion and Diapedesis	4.31E+00	4.23E-02	NaN
Day 0 vs Day 6	Death Receptor Signaling	4.29E+00	6.25E-02	2.449
Day 0 vs Day 6	Retinoic acid Mediated Apoptosis Signaling	4.25E+00	8.33E-02	2.236
Day 0 vs Day 6	Agranulocyte Adhesion and Diapedesis	3.94E+00	3.74E-02	NaN
Day 0 vs Day 8	Role of Hypercytokinemia/hyperchemokemia in the Pathogenesis of Influenza	1.70E+01	1.98E-01	4.123
Day 0 vs Day 8	Interferon Signaling	1.35E+01	3.06E-01	2.714
Day 0 vs Day 8	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	1.03E+01	9.62E-02	2.828
Day 0 vs Day 8	Activation of IRF by Cytosolic Pattern Recognition Receptors	7.81E+00	1.38E-01	1.667
Day 0 vs Day 8	Granulocyte Adhesion and Diapedesis	6.36E+00	6.35E-02	NaN
Day 0 vs Day 8	Coronavirus Pathogenesis Pathway	6.03E+00	5.91E-02	-2.111
Day 0 vs Day 8	Complement System	4.51E+00	1.35E-01	1
Day 0 vs Day 8	Agranulocyte Adhesion and Diapedesis	4.24E+00	4.67E-02	NaN
Day 0 vs Day 8	Role of PKR in Interferon Induction and Antiviral Response	4.19E+00	5.88E-02	2.449
Day 0 vs Day 8	Role of Hypercytokinemia/hyperchemokemia in the Pathogenesis of Influenza	1.70E+01	1.98E-01	4.123
Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway	2.14E+01	5.67E-02	2.828
Day 0 vs Day 10	IL-15 Signaling	2.04E+01	6.63E-02	NaN
Day 0 vs Day 10	B Cell Receptor Signaling	1.79E+01	5.55E-02	NaN
Day 0 vs Day 10	Communication between Innate and Adaptive Immune Cells	1.35E+01	3.88E-02	NaN
Day 0 vs Day 10	Interferon Signaling	1.24E+01	2.78E-01	2.53
Day 0 vs Day 10	Role of Hypercytokinemia/hyperchemokemia in the Pathogenesis of Influenza	1.10E+01	1.40E-01	3.464
Day 0 vs Day 10	Primary Immunodeficiency Signaling	7.59E+00	1.43E-01	NaN
Day 0 vs Day 10	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	4.20E+00	5.13E-02	2
Day 0 vs Day 10	Activation of IRF by Cytosolic Pattern Recognition Receptors	3.61E+00	7.69E-02	0.447
Day 0 vs Day 10	Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I	3.01E+00	1.30E-01	NaN
Day 0 vs Day 14	IL-15 Signaling	1.08E+02	2.05E-01	NaN
Day 0 vs Day 14	B Cell Receptor Signaling	9.91E+01	1.71E-01	NaN
Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway	9.24E+01	1.49E-01	NaN
Day 0 vs Day 14	Communication between Innate and Adaptive Immune Cells	8.17E+01	1.17E-01	NaN
Day 0 vs Day 14	Kinetochore Metaphase Signaling Pathway	1.54E+01	1.62E-01	3.207
Day 0 vs Day 14	Primary Immunodeficiency Signaling	1.06E+01	1.96E-01	NaN
Day 0 vs Day 14	Estrogen-mediated S-phase Entry	7.95E+00	2.69E-01	2.646
Day 0 vs Day 14	Mitotic Roles of Polo-Like Kinase	7.29E+00	1.36E-01	1.414
Day 0 vs Day 14	Cyclins and Cell Cycle Regulation	6.37E+00	1.07E-01	3
Day 0 vs Day 14	Role of CHK Proteins in Cell Cycle Checkpoint Control	5.48E+00	1.23E-01	-2.236

721

Figure 1




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

